Therapeutic Decision-Making for Gastrointestinal Ulcers in Veterinary Patients

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Therapeutic decision-making for gastrointestinal ulcers hinges on identifying the disrupted balance between mucosal defense and aggressive factors, with key etiologies including NSAID exposure, stress, neoplasia, and infection dictating whether acid suppression or cytoprotection is prioritized.
• Gastric mucosal integrity relies on mucus, bicarbonate, and robust blood flow, modulated by prostaglandins; NSAIDs disrupt this defense, while acid and pepsin represent aggressive factors, and ischemia impairs perfusion, leading to ulceration.
• Antisecretory agents like proton pump inhibitors (PPIs) and H2-receptor antagonists are crucial for raising gastric pH above 4 to facilitate healing, with PPIs offering more profound and prolonged suppression, while cytoprotectants such as sucralfate provide a physical barrier and stimulate repair.
• Species-specific metabolic differences, particularly slower drug metabolism in cats and production animal constraints like withdrawal periods, necessitate careful drug selection and dosing adjustments.
• Monitoring response involves assessing clinical signs like resolution of hematemesis and melena within 48-72 hours, alongside serial hematocrit measurements, with repeat endoscopy reserved for non-responders or suspected neoplasia.
• Enteral nutrition, when feasible, supports mucosal integrity by buffering acid and enhancing blood flow, serving as an adjunct to pharmacologic therapy, especially in critically ill patients.

Gastrointestinal ulceration represents a failure of mucosal defense against luminal aggressive factors, and therapy selection hinges on identifying which arm of that balance has been disrupted. This article provides a decision framework for veterinary students and practitioners confronting ulcer disease across species, from canine and feline patients to production animals. It answers three clinical questions: when to treat, which drug class to choose, and how to monitor response. The framework prioritizes mechanistic reasoning over rote protocol, because the same endoscopic lesion may demand opposite therapeutic strategies depending on its etiology.

The stomach normally integrates physical and chemical defense with controlled inflammation, a balance that fails under infection, ischemia, or drug injury. When that balance breaks, the resulting lesion is named by location and depth, but the therapeutic logic remains constant: remove the insult, restore perfusion, neutralize or reduce acid where appropriate, and support epithelial repair. This article covers the pharmacology of antisecretory agents, cytoprotectants, and emerging biomaterial approaches, then builds a species-aware decision tree for common clinical scenarios. Monitoring strategies, including when to repeat endoscopy and how to interpret clinical surrogates, are addressed in the final sections.

At a Glance

Physiology of Mucosal Defense and Ulcerogenesis

Gastric mucosal integrity depends on a continuous layer of mucus and bicarbonate, robust mucosal blood flow, and rapid epithelial restitution. Prostaglandins, particularly PGE2 and prostacyclin, coordinate these defenses by stimulating mucus and bicarbonate secretion, maintaining microvascular integrity, and modulating mucosal blood flow. When prostaglandin synthesis is suppressed by non-steroidal anti-inflammatory drugs, the mucosa loses its primary defense against luminal acid and pepsin. The resulting injury pattern is typically antral or pyloric, often with multiple shallow erosions that may progress to frank ulceration.

Acid and pepsin constitute the aggressive arm of the equation. Gastric acid secretion is driven by histamine, gastrin, and acetylcholine, converging on the parietal cell proton pump. Suppressing acid does not heal all ulcers, but it creates the pH environment in which endogenous repair mechanisms can operate. Pepsin, which is inactivated above pH 4, is a particular target of antisecretory therapy. The clinical corollary is that acid suppression must be sufficient to raise intragastric pH above this threshold for sustained periods, also reduce acid output.

Ischemia represents a third pathway to ulceration that is frequently overlooked. Hypovolemia, shock, and sepsis reduce mucosal perfusion, impairing bicarbonate delivery and allowing hydrogen ion back-diffusion. In critically ill patients, stress ulceration typically affects the gastric body and fundus, where metabolic demand is highest. Enteral nutrition, when feasible, enhances regional gastrointestinal blood flow and may reduce mucosal erosion formation, though it does not entirely prevent lesions. The decision to add pharmacologic prophylaxis must therefore account for perfusion status, also the presence of risk factors.

Pharmacologic Classes and Mechanisms

Antisecretory Agents

Histamine H2-receptor antagonists and proton pump inhibitors form the backbone of acid suppression in veterinary medicine. H2 antagonists competitively block histamine at the parietal cell, reducing basal and meal-stimulated acid secretion but leaving gastrin and cholinergic pathways partially intact. Proton pump inhibitors irreversibly bind the H+/K+ ATPase, the final common pathway of acid secretion, and therefore achieve more profound and prolonged suppression. The choice between these classes depends on the severity of the lesion, the need for rapid pH elevation, and species-specific pharmacokinetics.

Synthetic prostaglandin analogues occupy a distinct position. Enprostil, a PGE2 analogue, suppresses acid secretion by up to 80 percent for nearly 12 hours after a single dose while also inhibiting gastrin release and enhancing bicarbonate secretion. This dual action, reducing aggressive factors while supporting defensive ones, makes prostaglandin analogues particularly attractive for NSAID-induced injury. Their clinical use is limited by availability, cost, and dose-dependent gastrointestinal side effects including diarrhea.

Cytoprotective and Mucosal Coating Agents

Sucralfate, bismuth compounds, and misoprostol act through mechanisms that do not require profound acid suppression. Sucralfate polymerizes in acid to form a viscous gel that adheres to ulcer bases, while also stimulating local prostaglandin synthesis and growth factor binding. These agents are useful adjuncts in superficial erosions but are insufficient as monotherapy for deep or bleeding ulcers. Misoprostol, a synthetic PGE1 analogue, provides cytoprotection through receptor-mediated effects on mucus and bicarbonate secretion, though its antisecretory potency is modest compared with proton pump inhibitors.

Emerging Biomaterial Approaches

Bioadhesive hydrogels represent a newer strategy for local ulcer therapy. Recent work in porcine models demonstrates that thiourea-catechol hydrogels achieve rapid, pH-independent gelation and adhere to gastric ulcer sites for at least 48 hours after endoscopic delivery. These materials suppress inflammation and promote re-epithelialization and angiogenesis, suggesting a future role as delivery vehicles for growth factors or as physical barriers against luminal contents. Clinical translation in veterinary patients remains experimental, but the mechanism addresses a gap in current therapy: sustained local drug delivery at the ulcer bed.

Species Considerations in Drug Selection

Feline patients present particular challenges. Cats metabolize many antisecretory drugs more slowly than dogs, and their relatively alkaline gastric pH at baseline means that acid suppression targets differ. Proton pump inhibitors require careful attention to dosing frequency in cats, and H2 antagonists may be preferred when moderate suppression suffices. The feline predisposition to chronic kidney disease also complicates NSAID use, making ulcer prevention in this species a matter of avoiding the insult instead of treating its consequence.

Ruminants and horses rely heavily on hindgut fermentation, and oral antisecretory agents may alter abomasal or gastric pH in ways that affect digestion. Foals are particularly susceptible to gastric ulceration, and therapy must balance acid suppression against the need for normal protein digestion. Production animal practitioners must also consider withdrawal periods and extra-label drug use regulations, which vary by jurisdiction. The World Organization for Animal Health publishes international standards for veterinary drug use that inform these decisions, though national rules take precedence.

Diagnostic Reasoning Before Therapy

The first therapeutic decision is whether to treat at all. Superficial erosions in a patient with transient NSAID exposure may heal with drug withdrawal alone, while a perforating ulcer demands surgical intervention regardless of medical therapy. Endoscopic staging, when available, provides the most reliable basis for this decision. The Davis-Thompson Foundation pathology resources offer gross and histologic images that help students correlate endoscopic findings with tissue-level injury, a skill that directly informs treatment intensity.

Clinical signs alone are unreliable predictors of ulcer depth or bleeding risk. Hematemesis, melena, and anemia indicate significant hemorrhage, but their absence does not exclude ulceration. Conversely, vomiting in a patient with mild gastritis does not justify aggressive antisecretory therapy if the underlying cause is dietary indiscretion. The decision framework presented in the next section integrates history, physical examination, and available diagnostics to match therapy intensity to lesion severity.

Initial Assessment and Stabilization

The first decision in ulcer therapy is whether the patient requires emergency intervention. Hematemesis, melena, pallor, tachycardia, or a falling packed cell volume indicate active hemorrhage. These patients need intravenous fluid resuscitation, blood product support if available, and rapid endoscopic or surgical evaluation before gastroprotectant selection becomes the primary concern. The MSD Veterinary Manual provides species-specific guidance on shock management and transfusion thresholds that should inform this triage step.

For hemodynamically stable patients, the diagnostic sequence proceeds from confirmation of ulceration to identification of the inciting cause. Endoscopy remains the gold standard for confirming mucosal lesions and allows biopsy to distinguish inflammatory, neoplastic, or infectious etiologies. Where endoscopy is unavailable, response to empirical therapy combined with serial hematologic and biochemical monitoring may support a presumptive diagnosis, but this approach carries greater uncertainty.

Selecting the Primary Therapeutic Agent

The choice between antisecretory and cytoprotective therapy depends on the dominant pathogenic mechanism. Acid-driven ulcers, including those induced by nonsteroidal anti-inflammatory drugs (NSAIDs) or mast cell tumors, respond best to profound acid suppression. Proton pump inhibitors provide the most consistent and prolonged acid suppression and are the preferred first-line agents for gastric and duodenal ulcers in dogs and cats. Histamine type 2 receptor antagonists offer a reasonable alternative when cost or formulary constraints apply, though their less predictable suppression of meal-stimulated acid secretion makes them inferior for severe lesions.

Cytoprotective agents serve a complementary role. Sucralfate forms an adherent barrier over ulcerated mucosa and may be particularly useful for distal esophageal lesions where acid suppression alone leaves the mucosa exposed to refluxate. Prostaglandin analogues such as misoprostol address the specific pathophysiology of NSAID-induced injury by restoring mucosal blood flow and bicarbonate secretion. The historical prostaglandin analogue enprostil demonstrated both antisecretory and mucosal protective effects in human peptic ulcer disease, including suppression of basal and postprandial gastrin release, but veterinary experience with this class remains limited and current use centers on misoprostol Enprostil pharmacodynamic and therapeutic profile.

The following table summarizes the selection logic:

Monitoring Response and Adjusting Therapy

Clinical improvement should be assessed at defined intervals. Resolution of hematemesis and melena typically occurs within 48 to 72 hours of effective acid suppression. Persistent hemorrhage beyond this window warrants repeat endoscopy or surgical intervention. Appetite and activity level improve more gradually, often over 5 to 14 days.

Serial hematocrit measurement every 12 to 24 hours during the acute phase detects ongoing blood loss. A stable or rising hematocrit after initial fluid resuscitation indicates successful hemostasis. Biochemical monitoring is indicated for patients on prolonged proton pump inhibitor therapy, particularly those with pre-existing renal disease, as hypomagnesemia and electrolyte disturbances have been reported with extended use in human medicine.

Endoscopic re-evaluation is reserved for patients who fail to improve clinically, those with suspected neoplasia, or those with recurrent ulceration after apparent healing. Repeat endoscopy at 2 to 4 weeks confirms mucosal healing and allows re-biopsy of suspicious lesions.

Enteral Nutrition as Adjunctive Therapy

Enteral nutrition serves a dual role in ulcer management. It buffers gastric acid through the buffering capacity of food and stimulates mucosal blood flow through the cephalic and gastric phases of digestion. A review of enteral nutrition for stress ulcer prophylaxis found that intragastric administration of carbohydrate, lipid, or amino acid substrates reduced the occurrence of mucosal erosions in experimental models, though it did not entirely prevent their development Enteral nutrition effects on stress ulcer prophylaxis.

The practical implication is that early enteral feeding, when not contraindicated by active hemorrhage or ileus, should accompany pharmacologic therapy instead of replace it. Continuous rate infusion of a liquid diet provides more consistent gastric buffering than bolus feeding. Patients with perforated ulcers or those undergoing surgical repair require a period of nil per os followed by gradual reintroduction of feeding.

Recognizing Treatment Failure and Escalating Care

Treatment failure is defined as persistent hemorrhage, worsening clinical signs, or failure of endoscopic healing despite 2 weeks of appropriate therapy. The differential for non-response includes:

• Incorrect diagnosis, particularly undetected neoplasia or fungal infection
• Ongoing NSAID or corticosteroid administration
• Inadequate acid suppression due to dosing errors or drug interactions
• Recurrent foreign body or dietary indiscretion
• Portal hypertension with congestive gastropathy

When failure occurs, the clinician should revisit the diagnostic plan before simply changing drug class. Endoscopic biopsy is essential to exclude neoplasia, and histopathology should be reviewed by a specialist if the initial interpretation is uncertain. The Davis-Thompson Foundation maintains pathology teaching resources that can support interpretation of challenging gastrointestinal biopsy material.

Surgical intervention is indicated for perforation, uncontrolled hemorrhage, or obstructive lesions. Postoperative management requires continued acid suppression, analgesia without NSAIDs, and gradual reintroduction of enteral nutrition.

Documentation and Case Communication

Medical records should document the suspected etiology, the rationale for agent selection, the monitoring schedule, and the criteria that would trigger escalation. Serial photographs from endoscopy provide objective evidence of healing. Client communication must address the expected timeline for improvement, the importance of completing the full course of therapy, and the need to avoid NSAIDs or other ulcerogenic drugs during recovery.

For production animals, withdrawal periods for any medication used must be verified against current label information and regional regulations. The WOAH terrestrial animal health standards address residue monitoring principles that inform responsible drug use in food animals, and the AVMA practice resources provide additional guidance on extralabel drug use and professional obligations.

The monitoring checklist below summarizes the minimum parameters for follow-up:

Recognized Complications and Early Detection

The principal complications of ulcer therapy are hemorrhage, perforation, and gastric outflow obstruction secondary to cicatrisation. Each has a distinct temporal profile and requires a different monitoring strategy.

Hemorrhage is the most common serious complication. Early detection depends on serial assessment of packed cell volume, total solids, and mucosal color instead of waiting for overt hematemesis or melaena. A falling packed cell volume with stable hydration in a patient receiving gastroprotectants warrants immediate re-evaluation of the ulcer, not simply transfusion support. Occult bleeding can be tracked with serial fecal occult blood testing, although this lacks specificity in patients eating a meat-based diet.

Perforation presents as acute deterioration: tachyarrhythmia, worsening abdominal pain, rigid abdomen, or rapid cardiovascular collapse. In ruminants and horses, perforation may present as sudden severe colic or recumbency instead of localizing signs. Peritoneal fluid analysis showing degenerate neutrophils and intracellular bacteria supports the diagnosis. Imaging findings such as free peritoneal gas or focal peritonitis on ultrasonography should prompt surgical exploration without delay.

Gastric outflow obstruction develops over days to weeks. Repeated vomiting of food, progressive abdominal distension, and weight loss in a patient whose ulcer pain has otherwise improved should raise suspicion. Contrast radiography or ultrasonography demonstrating a thickened pyloric region with delayed gastric emptying confirms the diagnosis. Medical therapy will not resolve established cicatricial obstruction, surgical correction is required.

Common Errors and Corrective Actions

The most frequent error is continuing an ulcerogenic drug while treating the ulcer it caused. If the inciting agent can be withdrawn, it must be. When it cannot, such as with long-term corticosteroid therapy for immune-mediated disease, the clinician should document the rationale and increase monitoring frequency.

A second error is treating the ulcer but not the underlying disease. A gastric ulcer in a hypovolemic, hypotensive patient will not heal while perfusion remains inadequate. Similarly, an ulcer secondary to hepatic disease or mast cell neoplasia will recur unless the primary process is addressed.

A third error is switching antisecretory classes prematurely. Proton pump inhibitors require 3 to 5 days to reach steady-state acid suppression. Judging efficacy before that interval is unreliable. Conversely, continuing a drug that has clearly failed at an adequate dose for a full course wastes time and exposes the patient to adverse effects without benefit.

A fourth error is neglecting enteral nutrition. Enteral nutrition support for stress ulcer prophylaxis has been shown to reduce mucosal erosion formation, and withholding food from a patient with an ulcer removes a stimulus for mucosal repair. Early refeeding, where not contraindicated by perforation risk or surgical intervention, supports healing.

Troubleshooting Table

Limitations of Current Evidence

The veterinary literature on ulcer therapy is dominated by extrapolation from human medicine and by experimental models instead of clinical trials in spontaneous disease. The evidence base for cytoprotective agents is particularly thin. Reviews of medicinal plants and their bioactive compounds against ulcers describe promising experimental activity, but clinical applicability in veterinary patients remains uncertain. Similarly, curcumin as a protectant against esophageal and gastric disorders is supported by experimental data, yet no robust veterinary clinical trials establish its efficacy or optimal formulation.

Expert opinion differs on several points. Whether all patients receiving non-steroidal anti-inflammatory drugs require prophylactic gastroprotectants remains contested. The duration of therapy after ulcer healing is also debated, with some authorities recommending continued acid suppression during the period of epithelial remodelling and others favouring early discontinuation to avoid rebound hyperacidity. The role of prostaglandin analogues in routine practice is limited by cost and adverse effects, despite evidence of efficacy in peptic ulcer disease.

Referral, Consultation, and Reporting

Referral is indicated when endoscopic biopsy is required, when perforation or obstruction is suspected, or when a patient fails to respond to appropriate medical therapy within the expected interval. Specialist consultation should also be considered for recurrent ulceration without an identifiable cause, as this raises the possibility of gastrinoma or other neuroendocrine neoplasia.

Laboratory involvement extends beyond routine hematology and biochemistry. Histopathology of endoscopic biopsies distinguishes inflammatory from neoplastic disease. Bacterial culture and susceptibility testing may be warranted if Helicobacter-like organizms are identified and treatment is planned.

Regulatory reporting obligations vary by jurisdiction. Suspected adverse drug reactions to gastroprotectants should be reported through the relevant national pharmacovigilance scheme. In food-producing animals, withdrawal periods must be observed and documented, and international animal health standards may apply where trade implications exist. The AVMA practice resources provide guidance on professional obligations in the United States, while MSD Veterinary Manual offers species-specific reference material applicable across regions.

Frequently Asked Questions

How Do I Choose Therapy When Cost Limits the Owner's Options?

Prioritize the intervention that addresses the dominant pathogenic mechanism. If NSAID exposure or critical illness drives ulceration, discontinuing the offending agent and providing enteral nutrition may outperform adding a second drug. When a proton pump inhibitor is unaffordable, an H2-receptor antagonist remains a reasonable alternative, though acid suppression is less profound and more variable. Sucralfate suspension is inexpensive and useful for coating established ulcers, but it does not prevent acid injury. Discuss the trade-off explicitly with the owner: a shorter course of a more potent drug often costs less than prolonged combination therapy. Document the financial constraint and the rationale for the selected regimen in the medical record.

What Should I Do When Endoscopy Is Unavailable for Confirmation?

When endoscopy is not feasible, base the diagnosis on signalment, history, physical examination, and response to therapy. Hematemesis, melena, cranial abdominal pain, and anemia in a patient with recent NSAID exposure support a presumptive ulcer diagnosis. Perform serial packed cell volume and total protein measurements to track blood loss. If clinical signs resolve within 48 to 72 hours of empirical therapy, continue the planned course. If signs persist or deteriorate, pursue referral for endoscopy or advanced imaging instead of escalating empirical treatment blindly. The MSD Veterinary Manual provides species-specific guidance on ulcer presentation and diagnostic limitations in general practice.

How Does Monitoring Differ Between Dogs, Cats, and Large Animals?

Dogs tolerate repeated venepuncture and abdominal palpation well, so serial hematocrit and fecal occult blood testing are practical. Cats with gastric ulcers often present with chronic vomiting and weight loss instead of overt hemorrhage, and they are more prone to adverse effects from some antisecretory drugs, so monitor hepatic and renal parameters during prolonged therapy. In horses, gastric ulceration is frequently managed without endoscopy using empirical treatment and clinical response, but recurrence is common and requires re-evaluation of management factors. Ruminants and pigs present practical constraints: repeated handling causes stress that may worsen ulceration, so monitoring relies on production parameters, appetite, and fecal character. Consult AVMA practice resources for professional guidance on species-specific case management.

When Should I Add Enteral Nutrition to Pharmacologic Therapy?

Enteral nutrition should begin early in any patient with an ulcer that cannot eat normally for more than 24 to 48 hours. Intragastric feeding provides substrate for mucosal repair, enhances gastrointestinal blood flow, and may reduce the formation of macroscopic erosions, though it does not entirely prevent them. In critically ill patients, enteral nutrition may serve as adjunctive prophylaxis against stress ulceration, but it should not replace pharmacologic acid suppression in high-risk cases. Use a naso-esophageal or gastrostomy tube in small animals and an indwelling nasogastric tube in horses. Start with small, frequent meals or continuous infusion to avoid gastric distension. Reassess the need for parenteral nutrition if the patient cannot tolerate enteral feeding.

How Should I Document Ulcer Therapy and Communicate With the Referring Veterinarian?

Record the suspected aetiology, the diagnostic tests performed, the drugs prescribed with rationale, and the monitoring schedule. Note any financial constraints or owner concerns that influenced the plan. Include a clear recheck interval and criteria for escalation, such as persistent melena, declining packed cell volume, or worsening pain. When communicating with the referring veterinarian, state what was found, what was started, and what should trigger re-presentation. If referral was declined, document that discussion and the owner's decision. The Davis-Thompson Foundation pathology resources can help you describe gross and histopathologic findings accurately when biopsy material is available.

What Is the Role of Prostaglandin Analogues in Modern Ulcer Therapy?

Prostaglandin analogues such as misoprostol and enprostil suppress gastric acid secretion and enhance mucosal defensive factors, including bicarbonate secretion. Enprostil inhibits basal and postprandial gastrin release, a property distinct from H2-receptor antagonists. These drugs are most valuable for preventing NSAID-induced ulceration in patients that must continue NSAID therapy, particularly dogs with osteoarthritis. Their use is limited by dose-dependent diarrhea and cramping, and they are contraindicated in pregnant animals because of abortifacient effects. In horses, misoprostol has been used for gastric ulcer prophylaxis, but cost and adverse effects restrict routine use. Consult a current formulary for species-specific indications and contraindications before prescribing.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• Therapeutic Promises of Medicinal Plants in Bangladesh and Their Bioactive Compounds against Ulcers and Inflammatory Diseases.. 2021.
• Curcumin: A Potent Protectant against Esophageal and Gastric Disorders.. 2019.
• Enprostil. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of peptic ulcer disease.. 1987.
• Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures.. 1992.
• Bioadhesive hydrogels demonstrating pH-independent and ultrafast gelation promote gastric ulcer healing in pigs.. 2020.
• Use of enteral nutrition for stress ulcer prophylaxis.. 2001.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Therapeutic Decision-Making for Autoimmune Disease in Dogs
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Therapeutic Decision-Making for Bacterial Skin Infections in Dogs
• Therapeutic Decision-Making for Urinary Tract Infections in Dogs
• Decision Framework for Anticoagulant Therapy in Veterinary Patients

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.